Dr Mikkael Sekeres speaks to ecancer at the ASH 2019 meeting in Orlando about eligibility criteria in acute myeloid leukaemia (AML).
He explains that the first part of this work showed that eligibility criteria were unrelated to expected toxicities of drugs or the realised adverse effects on a clinical trial.
The second part of this research looked at data from patients who were found to be ineligable for studies after enrolment, but who were treated on the trial anyway. When adverse effects, remission rates and survival of eligible and ineligible patients were compared, no difference was found, suggesting the selection criteria was too restrictive.
Dr Sekeres concludes that the reason more patients aren't enrolled into clinical trials is that the eligibility criteria prevents clinicians from doing so, even when the criteria are not correlated with potential outcomes.